niche turns into a leukemic niche. While the altered expression of different extracellular matrix (ECM) elements within the leukemic niche has already been investigated, 6 the direct contribution of LSCs to the modification of the niche ECM has not been assessed systematically, and the prognostic relevance of alterations to the ECM homeostasis directly operated by LSCs, and AML cells remains untested. To this aim, we studied the transcriptional profile of ECM-related genes in LSCs, and applied the results to two AML cohorts to verify their prognostic potential.
The raw microarray profiles of normal HSCs, multipotent progenitors (MPPs), committed progenitors (megakaryocyte-erythrocyte progenitors, MEPs, common myeloid progenitors, CMPs, and granulocyte/monocyte progenitors, GMPs), LSCs, leukemia progenitor cells Table S1 ). Of them, the differential expression of the 15 most important genes, as resulted from the SVM algorithm, was validated via qPCR in the 65 AML patients of the Oulu retrospective cohort (Online Supplementary Table S2 and Online Supplementary Figure  S1 ). Grouping the precursors according to the 80 ECM genes by Ward's method or PCA followed by LDA resulted in three significant clusters; one containing only committed precursors (in grey), one containing only leukemic cells (in red), and the last containing leukemic cells admixed with normal HSCs and MPPs (in blue). Based on the proposed origin of LSCs from MPPs, 4 we called the leukemic cells within the blue cluster "early leukemic", and the ones within the red cluster "definitive leukemic" (Figure 1A-B) . Notably, the amount of LSC and LPC in the two subgroups was equal (Online Supplementary Figure  S2) , discarding possible quantitative interferences as confounding factors for the clustering procedures. Next, we standardized the leukemic precursors and the patient data together and observed that the samples from the early and definitive groups continued to cluster independently (albeit fragmenting in smaller subgroups), never mixing and partitioning patient data into the same groups (Online Supplemental Figure S3 ). Patient grouping into "early-type" and "definitive-type" resulted in significant differences in overall survival ( Figure 1C ), even when data were adjusted for karyotypical (P=0.038 in GSE10358 and 0.016 in TCGA LAML) or molecular abnormalities (adjustment for FLT3, P=0.031 in GSE10358 and 0.027 in TCGA LAML; adjustment for IDH1, P=0.041 in GSE10358 and 0.033 in TCGA LAML; adjustment for NPM1, P=0.033 in GSE10358 and 0.024 in TCGA LAML). The two groups also significantly differed in event-free survival (EFS) and disease-free survival (DFS) ( Figure 1D) . Also, Fisher's Exact test returned no significant associations between clustering into the two groups and any risk factor (Online Supplementary Table  S3) , and multivariate survival models returned significant values for DFS in TCGA (P=0.015, HR: 4.45 [95% CI: 1.33-14.8]) and for EFS in GSE10358 (P=0.017, HR: 5.1 [95% CI: 1.34-20]), further confirming the independent prognostic value of these observations. Finally, we noticed that including the ECM signature into Cox-PH or GLM models based on the National Comprehensive Cancer Network (NCCN guidelines) significantly increased the discriminatory ( Figure 1E ) and the classificatory ( Figure 1F ) power of the NCCN classifier. Concerning the functions of the differentially expressed ECM genes, we found that leukemic cells upregulate proteases/peptidases (mostly metalloproteinases), but downregulate cell-ECM binding molecules (Figure 2A) . Coherently, using the ontologies suggested by Naba et al., 7 we observed that the group of genes with the highest variance was that of the "ECM regulators" (to which proteolytic enzymes are large contributors), followed by the "Not available" group (genes not included in the Matrisome DB) and by ECM glycoproteins (mostly proteins involved in cell adhesion). The remaining groups of collagens, secreted factors, proteoglycans and ECM-affiliated proteins were only marginally impacted ( Figure  2B ). The analysis of LSC markers 8 showed no major differences in the early and definitive groups (Online Supplementary Figure S4 ) except for the hyaluronic acid receptor CD44, which was significantly upregulated in definitive leukemic cells ( Figure 2C) . Notably, while CD44 has no effect on patient survival per se (P=0.513 for OS and P=0.982 for DFS in TCGA LAML), the same receptor has been reported to interact with collagen IV and laminin β2, 9,10 and we found both COL4A5 and LAMB2 among the seven genes significantly upregulated in the definitive leukemic cells ( Figure 2D) . Coinciding with overall ontological data, this small network is significantly enriched for ECM remodeling and peptidase/metallopeptidase ( Figure 2E and Online Supplementary Table S4 ). Furthermore, this network also contains collagen XVIII (COL18A1), which has previously been associated with human and murine HSCs. Notably, the absolute levels of COL18A1 are lower in leukemic cells than in their normal counterparts ( Figure  2F ), but they are at their local highest in definitive leukemic cells, again remarking the peculiarities of this stage of leukemic development.
In this study, we show for the first time the existence of an "ECM signature" which is shared by leukemia precursor cells and circulating AML cells from patients. The most striking feature of the ECM signature was to partition leukemic precursors into two groups, which differed for a restricted set of ECM genes and for the expression of the CD44 receptor. CD44 belongs to a family of transmembrane glycoproteins whose primary function is to bind hyaluronic acid (HA), laminins, collagens, matrix metalloproteinases (MMPs), osteopontin, etc., 12 and this receptor has previously been implicated in cell migration, proliferation, differentiation, survival, and bone marrow homing of hematopoietic stem/progenitor cells as well as in the homing of LSCs to intra-and extra-medullary niches and in resistance to chemotherapy. 12 We observed that the leukemic precursors with a higher expression of CD44 (the group of cells we called "definitive leukemic cells") also exhibit a parallel upregulation of genes whose products interact directly (COL4A5, LAMB2) 9,10 or indirectly (MMP2, COL18A1) 12 with CD44 and downregulation of MMP9 (which directly interacts with CD44 but whose levels correlate inversely with patient prognosis), 13 suggesting that the establishment of a "CD44-ECM network", rather than the expression of CD44 alone, is a crucial step in the progression of leukemic cells towards an aggressive phenotype. This also seems to be supported by the observation that, in two independent cohorts, patients with an ECM profile similar to that of the definitive leukemic cells showed significantly shorter survival (overall and endpoint), independently from well-known karyotypical or molecular drivers of AML. Notably, other genes upregulated in definitive leukemic cells include the matrix metalloproteinase 2 (MMP2), a disintegrin and metalloprotease domain 17 (ADAM17) and cathepsin G (CTSG), constituting a proteolytic subnetwork that sits well with the overall upregulation of proteases which we observe in the ECM signature and that others have already reported in AML.
14 Also, MMP2 has been implicated in AML invasiveness, 15 and ADAM17 seems to play a central role in the survival of leukemic cells via the activation of the Lyn/Akt survival pathway. 16 In conclusion, the correlation of the ECM signature with AML outcome and leukemic precursor subtypes suggests a central role for ECM alteration in AML biology and encourages further studies to understand the regulatory mechanisms controlling it. haematologica 2017; 102:e247
